Björn Bielec

Dr. Björn Bielec

University of Vienna
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SHSonja Hager
Sonja Hager
KKKatharina Korbula
Katharina Korbula
BBBjörn Bielec
Björn Bielec
Michael GruschMichael Grusch
Michael Grusch
CPChristine Pirker
Christine Pirker
PHPetra Heffeter
Petra Heffeter
Due to their high biological activity, thiosemicarbazones have been developed for treatment of diverse diseases, including cancer, resulting in multiple clinical trials especially of the lead compound Triapine. During the last years, a novel subclass of anticancer thiosemicarbazones has attracted substantial interest based on their enhanced cytotoxic activity. Increasing evidence suggests that the double-dimethylated Triapine derivative Me2NNMe2 differs from Triapine not only in its efficacy but also in its mode of action. Here we show that Me2NNMe2- (but not Triapine)-treated cancer cells exhibit all hallmarks of paraptotic cell death including, besides the appearance of endoplasmic reticulum (ER)-derived vesicles, also mitochondrial swelling and caspase-independent cell death via the MAPK signaling pathway. Subsequently, we uncover that the copper complex of Me2NNMe2 (a supposed intracellular metabolite) inhibits the ER-resident protein disulfide isomerase, resulting in a specific form of ER stress based on disruption of the Ca2+ and ER thiol redox homeostasis. Our findings indicate that compounds like Me2NNMe2 are of interest especially for the treatment of apoptosis-resistant cancer and provide new insights into mechanisms underlying drug-induced paraptosis.

1 June 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
BBBjörn Bielec
Björn Bielec
HSHemma Schueffl
Hemma Schueffl
ATAlessio Terenzi
Alessio Terenzi
WBWalter Berger
Walter Berger
PHPetra Heffeter
Petra Heffeter
CKChristian Kowol
Christian Kowol

7 July 2017 in The Analyst
Verified
Journal Article
Open access
PDF file
KPKarla Pelivan
Karla Pelivan
LFLisa Frensemeier
Lisa Frensemeier
UKUwe Karst
Uwe Karst
GKGunda Koellensperger
Gunda Koellensperger
BBBjörn Bielec
Björn Bielec
CKChristian Kowol
Christian Kowol
α-N-Heterocyclic thiosemicarbazones are among the most promising ribonucleotide reductase inhibitors identified so far. Triapine, the most prominent representative of this class of substances, has been investigated in multiple phase I and II clinical trials. With regard to clinical practice, Triapine showed activity against hematological diseases, but ineffectiveness against a variety of solid tumors. However, the reasons are still vague and the amount of ADME (absorption, distribution, metabolism and excretion) data for Triapine available in the literature is very limited. Therefore, different analytical tools were used to investigate the metabolism of Triapine including electrochemical oxidations, liver microsomes and in vivo samples from mice. The main metabolic reactions, observed by all three methods, were dehydrogenation and hydroxylations, confirming that electrochemistry, as a purely instrumental approach, can be applied for the simulation of metabolic pathways. The dehydrogenated metabolite M1 was identified as a thiadiazole ring-closed oxidation product of Triapine. From a biological point of view, M1, as a key metabolite, is of interest since the crucial chemical property of α-N-heterocyclic thiosemicarbazones to bind metal ions is lost and cytotoxicity studies showed no anticancer activity of M1. The in vivo data of the urine samples revealed very high levels of the metabolites and Triapine itself already 15 min after treatment. This clearly indicates that Triapine is rapidly metabolised and excreted, which represents an important step forward to understand the possible reason for the inefficiency of Triapine against solid tumors.

4 March 2020 in Molecules
Verified
Journal Article
Open access
PDF file
BBBjörn Bielec
Björn Bielec
IPIsabella Pötsch
Isabella Pötsch
EAEsra Ahmed
Esra Ahmed
PHPetra Heffeter
Petra Heffeter
BKBernhard K. Keppler
Bernhard K. Keppler
CKChristian Kowol
Christian Kowol
Tyrosine kinase inhibitors revolutionized cancer therapy but still evoke strong adverse effects that can dramatically reduce patients’ quality of life. One possibility to enhance drug safety is the exploitation of prodrug strategies to selectively activate a drug inside the tumor tissue. In this study, we designed a prodrug strategy for the approved c-MET, ALK, and ROS1 tyrosine kinase inhibitor crizotinib. Therefore, a boronic-acid trigger moiety was attached to the 2-aminopyridine group of crizotinib, which is a crucial position for target kinase binding. The influence of the modifications on the c-MET- and ALK-binding ability was investigated by docking studies, and the strongly reduced interactions could be confirmed by cell-free kinase inhibition assay. Furthermore, the newly synthesized compounds were tested for their activation behavior with H2O2 and their stability in cell culture medium and serum. Finally, the biological activity of the prodrugs was investigated in three cancer cell lines and revealed a good correlation between activity and intrinsic H2O2 levels of the cells for prodrug A. Furthermore, the activity of this prodrug was distinctly reduced in a non-malignant, c-MET expressing human lung fibroblast (HLF) cell line.

1 May 2015 in Tetrahedron
Verified
Journal Article
Closed access
Michal KohoutMichal Kohout
Michal Kohout
BBBjörn Bielec
Björn Bielec
PSPatrick Steindl
Patrick Steindl
GTGünter Trettenhahn
Günter Trettenhahn
WLWolfgang Lindner
Wolfgang Lindner

27 November 2025 in Organic Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
SMSatenik Mkrtchyan
Satenik Mkrtchyan
VPVishal B. Purohit
Vishal B. Purohit
OSOleksandr Shalimov
Oleksandr Shalimov
YKYevhen Karpun
Yevhen Karpun
DPDr. Ronak Prajapati
Dr. Ronak Prajapati
Viktor IaroshenkoViktor Iaroshenko
Viktor Iaroshenko
This study presents an advanced approach for the reduction of nitroarenes to anilines, employing cucurbit[7]uril as a catalyst and ammonia borane as a hydrogen source, signifying noteworthy progression in photochemical supramolecular catalysis.